...
首页> 外文期刊>Alimentary pharmacology & therapeutics. >Review article: gastrointestinal amyloidosis - clinical features, diagnosis and therapy.
【24h】

Review article: gastrointestinal amyloidosis - clinical features, diagnosis and therapy.

机译:审查文章:胃肠道淀粉样症状,临床特征,诊断和治疗。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Amyloidosis is one of the unusual diseases about which a physician may not think when it is affecting the patient. During the last three decades, there has been an enormous progress in the understanding of the chemical nature, classification, pathogenesis, clinical features, diagnostic measures and therapy of this disorder. AIM: To provide an updated review of amyloidosis affecting the gastrointestinal tract. METHODS: Review of current medical literature. RESULTS: Amyloid proteins (irrespective of the type) can deposit in various parts of the gastrointestinal tract and liver resulting in symptoms of abdominal pain, dysmotility, diarrhoea, gastrointestinal bleeding, hepatomegaly and even portal hypertension with its associated complications. Definitive diagnosis can only be made by histological examination of the affected organ. Disease modifying treatment with high-dose chemotherapy followed by autologous stem-cell transplantation has shown promise. Liver transplantation is an option for a select group of patients. CONCLUSIONS: Suspicion of gastrointestinal amyloidosis in patients without known history of amyloidosis is difficult, but should be considered in those older than 30 years with unexplained diarrhoea, weight loss, autonomic dysfunction, malabsorption or proteinuria. While most gastrointestinal complications are managed symptomatically, causal therapy is reserved for a select few from various subtypes of this disorder.
机译:背景:淀粉样症是一个不寻常的疾病之一,医生在影响患者时可能不思考的疾病之一。在过去三十年中,了解对这种疾病的化学性质,分类,发病机制,临床特征,诊断措施和治疗的理解存在巨大进展。目的:提供影响胃肠道的淀粉样症状的更新审查。方法:当前医学文献综述。结果:淀粉样蛋白蛋白(无论类型)可以沉积在胃肠道和肝脏的各个部分中沉积,导致腹痛,缺陷,腹泻,胃肠道出血,肝肿大甚至门静脉高血压的症状导致其相关并发症。明确的诊断只能通过受影响器官的组织学检查来进行。用高剂量化疗的疾病改性治疗,然后进行自体茎细胞移植表明了承诺。肝移植是选择患者组的一种选择。结论:难以怀疑淀粉样蛋白病史的患者胃肠道淀粉样蛋白病,但应在30年龄的腹泻,减肥,自主功能障碍,不良药物或蛋白尿中的患者中考虑。虽然大多数胃肠道并发症进行治疗,但是因这些疾病的各种亚型中的选择少数人保留了因果疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号